Stock COR CENCORA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cencora, Inc.

Equities

COR

US03073E1055

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
240.9 USD +0.47% Intraday chart for Cencora, Inc. +0.73% +17.29%
Apr. 22 Mizuho Securities Adjusts Price Target on Cencora to $245 From $224 MT
Apr. 17 Cencora Insider Sold Shares Worth $2,553,860, According to a Recent SEC Filing MT

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,151 19,785 24,820 28,048 36,148 48,000 - -
Enterprise Value (EV) 1 17,950 19,307 28,957 30,363 38,343 49,806 45,764 44,284
P/E ratio 20.4 x -5.82 x 16.2 x 16.8 x 21.1 x 22.8 x 21.1 x 18.8 x
Yield 1.94% 1.71% 1.49% 1.36% - 0.85% 0.88% 0.92%
Capitalization / Revenue 0.1 x 0.1 x 0.12 x 0.12 x 0.14 x 0.16 x 0.15 x 0.15 x
EV / Revenue 0.1 x 0.1 x 0.14 x 0.13 x 0.15 x 0.17 x 0.15 x 0.13 x
EV / EBITDA 7.63 x 7.77 x 9.73 x 8.55 x 10.4 x 12.3 x 10.7 x 9.78 x
EV / FCF 8.83 x 10.5 x 13 x 13.8 x 11.1 x 19.9 x 15.4 x 14.8 x
FCF Yield 11.3% 9.52% 7.7% 7.27% 9.01% 5.03% 6.49% 6.74%
Price to Book 5.91 x -19.4 x 111 x 401 x - 31.3 x 19.8 x 12.9 x
Nbr of stocks (in thousands) 208,326 204,142 207,787 207,258 200,854 199,270 - -
Reference price 2 82.33 96.92 119.4 135.3 180.0 240.9 240.9 240.9
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 179,589 189,894 213,989 238,587 262,173 292,179 310,862 329,087
EBITDA 1 2,354 2,485 2,977 3,553 3,702 4,057 4,280 4,527
EBIT 1 2,051 2,204 2,648 3,163 3,289 3,614 3,863 4,094
Operating Margin 1.14% 1.16% 1.24% 1.33% 1.25% 1.24% 1.24% 1.24%
Earnings before Tax (EBT) 1 967.1 -5,294 2,222 2,183 2,161 2,430 2,613 2,869
Net income 1 855.4 -3,409 1,540 1,699 1,745 2,069 2,184 2,416
Net margin 0.48% -1.8% 0.72% 0.71% 0.67% 0.71% 0.7% 0.73%
EPS 2 4.040 -16.65 7.390 8.040 8.530 10.55 11.44 12.84
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,507 2,971 2,985
FCF margin 1.13% 0.97% 1.04% 0.92% 1.32% 0.86% 0.96% 0.91%
FCF Conversion (EBITDA) 86.4% 73.94% 74.85% 62.11% 93.27% 61.81% 69.4% 65.95%
FCF Conversion (Net income) 237.77% - 144.71% 129.9% 197.85% 121.21% 136.02% 123.58%
Dividend per Share 2 1.600 1.660 1.780 1.840 - 2.044 2.110 2.217
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 58,912 59,629 57,719 60,065 61,174 62,847 63,457 66,947 68,922 72,253 70,758 73,578 75,308 76,549 75,076
EBITDA 1 789.9 845.6 1,014 853.9 839.4 833.8 1,033 927.4 907.3 990.6 1,103 975.4 958.2 1,033 1,173
EBIT 1 694.1 749.1 916.6 756.2 741.5 733.7 932.1 822.3 801 885.7 997.4 873.3 858 949.9 1,073
Operating Margin 1.18% 1.26% 1.59% 1.26% 1.21% 1.17% 1.47% 1.23% 1.16% 1.23% 1.41% 1.19% 1.14% 1.24% 1.43%
Earnings before Tax (EBT) 1 - 596.2 728.2 476.3 382.3 593.5 512.1 608.8 446.4 783.4 731.7 622.2 553.7 650.8 833
Net income 1 437.7 449.1 548 407 294.7 479.7 435.4 479.6 350.6 601.5 587 481.4 468 546.1 657.1
Net margin 0.74% 0.75% 0.95% 0.68% 0.48% 0.76% 0.69% 0.72% 0.51% 0.83% 0.83% 0.65% 0.62% 0.71% 0.88%
EPS 2 2.080 2.130 2.590 1.920 1.400 2.330 2.130 2.350 1.720 2.980 2.992 2.494 2.439 2.842 3.438
Dividend per Share 2 0.4600 0.4600 0.4600 0.4600 0.4600 0.4850 0.4850 0.4850 - - 0.5072 0.5072 0.5072 0.5205 0.5205
Announcement Date 11/4/21 2/2/22 5/4/22 8/3/22 11/3/22 2/1/23 5/2/23 8/2/23 11/2/23 1/31/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 799 - 4,137 2,315 2,195 1,806 - -
Net Cash position 1 - 478 - - - - 2,236 3,716
Leverage (Debt/EBITDA) 0.3393 x - 1.39 x 0.6515 x 0.593 x 0.4451 x - -
Free Cash Flow 1 2,034 1,837 2,228 2,207 3,453 2,507 2,971 2,985
ROE (net income / shareholders' equity) 28.3% 152% - 39,497% 473% 199% 108% 78.7%
ROA (Net income/ Total Assets) 2.23% 3.93% 3.03% 2.98% 2.93% 3.53% 3.51% 3.64%
Assets 1 38,421 -86,793 50,806 56,949 59,560 58,529 62,274 66,286
Book Value Per Share 2 13.90 -4.990 1.070 0.3400 - 7.700 12.20 18.70
Cash Flow per Share 2 11.10 10.80 12.80 12.80 19.10 17.20 21.20 21.60
Capex 1 310 370 438 496 458 499 535 554
Capex / Sales 0.17% 0.19% 0.2% 0.21% 0.17% 0.17% 0.17% 0.17%
Announcement Date 11/7/19 11/5/20 11/4/21 11/3/22 11/2/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cencora, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
240.9 USD
Average target price
253.7 USD
Spread / Average Target
+5.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-1.93% 24.52B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. COR Stock
  4. Financials Cencora, Inc.